Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer.
Ovarian cancer remains difficult to treat mainly due to presentation of the disease at an advanced stage. Conditionally-replicating adenoviruses (CRAds) are promising anti-cancer agents that selectively kill the tumor cells. The present study evaluated the efficacy of a novel CRAd (Ad5/3-CXCR4-TIMP2...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3192051?pdf=render |
| _version_ | 1818133913898319872 |
|---|---|
| author | Sherry W Yang Diptiman Chanda James J Cody Angel A Rivera Reinhard Waehler Gene P Siegal Joanne T Douglas Selvarangan Ponnazhagan |
| author_facet | Sherry W Yang Diptiman Chanda James J Cody Angel A Rivera Reinhard Waehler Gene P Siegal Joanne T Douglas Selvarangan Ponnazhagan |
| author_sort | Sherry W Yang |
| collection | DOAJ |
| description | Ovarian cancer remains difficult to treat mainly due to presentation of the disease at an advanced stage. Conditionally-replicating adenoviruses (CRAds) are promising anti-cancer agents that selectively kill the tumor cells. The present study evaluated the efficacy of a novel CRAd (Ad5/3-CXCR4-TIMP2) containing the CXCR4 promoter for selective viral replication in cancer cells together with TIMP2 as a therapeutic transgene, targeting the matrix metalloproteases (MMPs) in a murine orthotopic model of disseminated ovarian cancer. An orthotopic model of ovarian cancer was established in athymic nude mice by intraperitonal injection of the human ovarian cancer cell line, SKOV3-Luc, expressing luciferase. Upon confirmation of peritoneal dissemination of the cells by non-invasive imaging, mice were randomly divided into four treatment groups: PBS, Ad-ΔE1-TIMP2, Ad5/3-CXCR4, and Ad5/3-CXCR4-TIMP2. All mice were imaged weekly to monitor tumor growth and were sacrificed upon reaching any of the predefined endpoints, including high tumor burden and significant weight loss along with clinical evidence of pain and distress. Survival analysis was performed using the Log-rank test. The median survival for the PBS cohort was 33 days; for Ad-ΔE1-TIMP2, 39 days; for Ad5/3-CXCR4, 52.5 days; and for Ad5/3-CXCR4-TIMP2, 63 days. The TIMP2-armed CRAd delayed tumor growth and significantly increased survival when compared to the unarmed CRAd. This therapeutic effect was confirmed to be mediated through inhibition of MMP9. Results of the in vivo study support the translational potential of Ad5/3-CXCR4-TIMP2 for treatment of human patients with advanced ovarian cancer. |
| first_indexed | 2024-12-11T09:00:17Z |
| format | Article |
| id | doaj.art-a89e8f6556d14978a92b7d720dbc70b6 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T09:00:17Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a89e8f6556d14978a92b7d720dbc70b62022-12-22T01:13:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01610e2513110.1371/journal.pone.0025131Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer.Sherry W YangDiptiman ChandaJames J CodyAngel A RiveraReinhard WaehlerGene P SiegalJoanne T DouglasSelvarangan PonnazhaganOvarian cancer remains difficult to treat mainly due to presentation of the disease at an advanced stage. Conditionally-replicating adenoviruses (CRAds) are promising anti-cancer agents that selectively kill the tumor cells. The present study evaluated the efficacy of a novel CRAd (Ad5/3-CXCR4-TIMP2) containing the CXCR4 promoter for selective viral replication in cancer cells together with TIMP2 as a therapeutic transgene, targeting the matrix metalloproteases (MMPs) in a murine orthotopic model of disseminated ovarian cancer. An orthotopic model of ovarian cancer was established in athymic nude mice by intraperitonal injection of the human ovarian cancer cell line, SKOV3-Luc, expressing luciferase. Upon confirmation of peritoneal dissemination of the cells by non-invasive imaging, mice were randomly divided into four treatment groups: PBS, Ad-ΔE1-TIMP2, Ad5/3-CXCR4, and Ad5/3-CXCR4-TIMP2. All mice were imaged weekly to monitor tumor growth and were sacrificed upon reaching any of the predefined endpoints, including high tumor burden and significant weight loss along with clinical evidence of pain and distress. Survival analysis was performed using the Log-rank test. The median survival for the PBS cohort was 33 days; for Ad-ΔE1-TIMP2, 39 days; for Ad5/3-CXCR4, 52.5 days; and for Ad5/3-CXCR4-TIMP2, 63 days. The TIMP2-armed CRAd delayed tumor growth and significantly increased survival when compared to the unarmed CRAd. This therapeutic effect was confirmed to be mediated through inhibition of MMP9. Results of the in vivo study support the translational potential of Ad5/3-CXCR4-TIMP2 for treatment of human patients with advanced ovarian cancer.http://europepmc.org/articles/PMC3192051?pdf=render |
| spellingShingle | Sherry W Yang Diptiman Chanda James J Cody Angel A Rivera Reinhard Waehler Gene P Siegal Joanne T Douglas Selvarangan Ponnazhagan Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer. PLoS ONE |
| title | Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer. |
| title_full | Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer. |
| title_fullStr | Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer. |
| title_full_unstemmed | Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer. |
| title_short | Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer. |
| title_sort | conditionally replicating adenovirus expressing timp2 increases survival in a mouse model of disseminated ovarian cancer |
| url | http://europepmc.org/articles/PMC3192051?pdf=render |
| work_keys_str_mv | AT sherrywyang conditionallyreplicatingadenovirusexpressingtimp2increasessurvivalinamousemodelofdisseminatedovariancancer AT diptimanchanda conditionallyreplicatingadenovirusexpressingtimp2increasessurvivalinamousemodelofdisseminatedovariancancer AT jamesjcody conditionallyreplicatingadenovirusexpressingtimp2increasessurvivalinamousemodelofdisseminatedovariancancer AT angelarivera conditionallyreplicatingadenovirusexpressingtimp2increasessurvivalinamousemodelofdisseminatedovariancancer AT reinhardwaehler conditionallyreplicatingadenovirusexpressingtimp2increasessurvivalinamousemodelofdisseminatedovariancancer AT genepsiegal conditionallyreplicatingadenovirusexpressingtimp2increasessurvivalinamousemodelofdisseminatedovariancancer AT joannetdouglas conditionallyreplicatingadenovirusexpressingtimp2increasessurvivalinamousemodelofdisseminatedovariancancer AT selvaranganponnazhagan conditionallyreplicatingadenovirusexpressingtimp2increasessurvivalinamousemodelofdisseminatedovariancancer |